In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research Report). The company’s shares opened today at $0.96.
According to TipRanks, Selvaraju is an analyst with an average return of -23.6% and a 26.00% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Enlivex, Axsome Therapeutics, and Inovio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Inovio Pharmaceuticals with a $2.00 average price target.
See today’s best-performing stocks on TipRanks >>
INO market cap is currently $243.6M and has a P/E ratio of -0.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Read More on INO:
